Pricing Log in Create free account

Axsome Therapeutics, Inc. (AXSM) vs Caris Life Sciences,�Inc. (CAI)

Axsome Therapeutics, Inc. and Caris Life Sciences,�Inc. are both Biotechnology companies. Axsome Therapeutics, Inc. and Caris Life Sciences,�Inc. are of similar size ($7.4B and $6.8B). Axsome Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Caris Life Sciences,�Inc. trades at 73.9×. Caris Life Sciences,�Inc. grew revenue faster over the last twelve months: 68.8% against 54.2%. Caris Life Sciences,�Inc. has the higher net margin (9.16% vs −18.2%) and the higher return on invested capital (33.0% vs 0.00%). Across the 17 metrics below, Caris Life Sciences,�Inc. leads on 16 and Axsome Therapeutics, Inc. on 1.

Valuation

Metric AXSM CAI Biotechnology median
P/E n/m 73.94 10.60
P/S 8.01 6.80 9.40
P/B 65.72 11.15 2.13
Price to free cash flow n/m 246.58 25.18
EV/EBITDA n/m 40.62 0.66
EV/Sales 7.79 6.44 9.02
Earnings yield (2.31%) 1.35% (32.88%)
Free cash flow yield (1.19%) 0.41% (23.13%)

Profitability

Metric AXSM CAI Biotechnology median
Gross margin 93.25% 69.09% 68.51%
Operating margin (17.45%) 13.35% 0.00%
Net margin (18.18%) 9.16% 0.00%
Free cash flow margin (9.55%) 2.76% 0.00%
Return on equity (175.59%) 17.19% (51.96%)
Return on assets (21.03%) 8.58% (46.06%)
Return on invested capital 0.00% 32.96% 0.00%

Growth

Metric AXSM CAI Biotechnology median
Revenue growth (TTM) 54.16% 68.84% 6.76%
EPS growth (last fiscal year) 38.56% 69.79% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric AXSM CAI Biotechnology median
Debt to equity 1.21 0.62 0.00
Current ratio 1.42 6.71 4.97
Net debt to EBITDA 1.29 (5.23) 1.01

Dividend

Metric AXSM CAI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AXSM CAI Biotechnology median
Market cap 6.83b 7.36b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack